G
Geneoscopy
Geneoscopy is developing a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples
About Geneoscopy
Geneoscopy is a healthcare startup that operates in the medical diagnostics market, specifically focusing on gastrointestinal diseases. The company's mission is to empower patients and healthcare providers by offering innovative, non-invasive tests that can detect, prevent, and monitor diseases such as colorectal cancer, ulcerative colitis, and Crohn's disease.
Read full description
Geneoscopy's business model revolves around its proprietary stool-derived eukaryotic RNA (seRNA) technology platform. In simple terms, this technology allows for the analysis of stool samples to detect signs of disease. This approach is a significant departure from traditional methods like colonoscopies, which are invasive and often inconvenient for patients. As a result, Geneoscopy's tests are safe, effective, and accessible, making them an attractive option for patients and healthcare providers alike.
The company primarily serves patients who are eligible for colorectal cancer screening but have not undergone it due to the invasive nature of traditional methods. With colorectal cancer being the second deadliest cancer in the US, Geneoscopy's services address a significant need in the market.
Geneoscopy generates revenue by selling its diagnostic tests to healthcare providers and patients. The company's commitment to early cancer detection and the increasing acceptance of diagnostics in managing gastrointestinal diseases suggest a promising future for the business.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Maryland Heights, United States
- Employees
- 70
- Open positions
- 11
- Dealroom signal
- 80.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Geneoscopy.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2025 | $105M | $420M | LabCorp · Petrichor · SAGES Ingenuity · Morningside | ↗ |
| SERIES BOther financing | Nov 2021 | $105M | $420M | Cultivation Capital · Morningside · Innovatus Capital Partners · Rodger Riney | ↗ |
Growth signals
Latest recorded traffic for Geneoscopy is 4.1K monthly website visits, up 13.9% over the last three months. Geneoscopy's team grew 6.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Damae MedicalMedical device capable of seeing biological tissues in depth, at a cellular level and in vivo |
Paris, France | Operational | 49 | $27M | $66M |
 ALTx TherapeuticsFirst-in-class precision oncology targeting immortal cancer cell pathways. |
Houghton and Wyton, United Kingdom | Operational | |||
 Kodiform TherapeuticsA drug discovery company with an initial focus on cancer |
London, United Kingdom | Operational | |||
 SpliceorRNA trans-splicing gene therapies for aggressive cancers |
Cambridge, United Kingdom | Operational | |||
 VectiopepDevelop cancer immunotherapy |
Tartu, Estonia | Operational | |||
 Ysotope TheranosticsTargeted radiopharmaceuticals for precision oncology |
Madrid, Spain | Operational | |||
 AtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance |
L'Hospitalet de Llobregat, Spain | Operational | |||
 OncoLizeInjectable drug depots to treat tumors from the inside |
Maastricht, Netherlands | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Dorm Room Fund
Missouri Technology Corporation
Billiken Angels Network
Series A7 investors entered at this stage
Cultivation Capital- NANT Asset
Morningside
Innovatus Capital Partners- RRRodger Riney
LabCorp
Lightchain
Series B and later4 investors entered at this stage
Bio-Rad Laboratories
Petrichor
SAGES Ingenuity
Varia Ventures
Other known investors2 additional known investors
Sling Health
Washington University School Of Medicine
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Geneoscopy on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Geneoscopy’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.